SELLAS Life Sciences Group, Inc. SLS R2K
Healthcare · Biotechnology · United States
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
READ MORE ›$9.31
+444.44% 1Y
Market & Price
Market Cap
$1.73B
Current Price
$9.31
High / Low (52W)
$9.31 / $1.39
Beta
2.24
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$0.46
Price to Book
20.11
P/S
-
EV/EBITDA
-
Dividend Yield
-
Profitability & Returns
ROCE
-39.64%
ROE
-43.59%
ROA
-25.45%
Profit Margin
0.00%
Op Margin
0.00%
EPS (Latest Qtr)
$-0.05
EPS (TTM)
$-0.23
Balance Sheet & Liquidity
Debt/Equity
0.81
Quick Ratio
16.59
Current Ratio
17.22
Debt
$871.00K
Total Assets
$78.34M
Current Assets
$75.21M
Working Capital
$68.19M
Ownership
Promoter Holding
0.43%
Chg in Prom Hold
-
FII / Inst Holding
29.22%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$1.63B
Total Revenue (TTM)
-
EBITDA
-
Free Cash Flow
$-17.66M
Operating Cash Flow
$-28.16M
Shares Outstanding
186.03M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-33.33%
Profit 5Y
11.65%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
- Profit CAGR of 11.7% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -33.3% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SLS SELLAS Life Sciences Group, Inc. R2K | 9.31 | - | $1.73B | - | -39.64% | -43.59% | -33.33% | 11.65% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 5.70M | 1.90M | 0 | 1.00M | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 1.45M | 1.23M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.06M | 6.87M | 7.08M | 8.26M | 9.25M |
| Operating Income | -6.89M | - | -11.85M | -15.78M | -10.57M | -8.91M | -9.08M | -8.63M | -8.97M | -9.29M | -6.47M | -5.09M | -4.91M | -4.46M | - | - | - | - | - | - | -4.06M | -4.27M | -4.49M | -2.25M | -4.45M | -6.98M | -16.73M | -8.62M | -7.15M | -11.28M | -9.05M | -9.36M | -9.64M | -7.62M | - | -6.06M | -6.87M | -7.08M | -8.26M | -9.25M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.06M | -6.87M | -7.08M | -8.26M | -9.25M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.81M | -6.60M | -6.79M | -7.66M | -8.41M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -6.93M | -5.52M | -2.54M | -19.94M | -6.17M | -10.54M | -15.66M | -18.03M | -16.49M | 5.39M | -6.93M | -4.60M | -5.91M | -4.46M | -8.00M | -6.06M | -290.00K | -4.54M | -3.13M | -4.20M | -4.14M | -4.42M | -4.47M | -2.40M | -4.61M | -7.08M | -16.74M | -8.41M | -7.02M | -11.10M | -8.84M | -9.27M | -9.57M | -7.47M | - | -5.81M | -6.60M | -6.79M | -7.66M | -8.41M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | 0.58 | - | - | -0.22 | - | - | - | - | - | - | - | - | -0.66 | -0.53 | -0.16 | -0.30 | -0.45 | -1.05 | -0.41 | -0.34 | -0.47 | -0.31 | -0.33 | -0.21 | -0.13 | -0.10 | -0.07 | -0.07 | -0.06 | - | -0.05 |
| R&D Expense | 3.63M | - | 6.77M | 8.07M | 7.03M | 5.83M | 7.20M | 5.74M | 5.44M | 6.17M | 3.62M | 2.18M | 1.83M | 1.07M | 1.80M | 1.59M | 1.72M | 1.86M | 1.38M | 1.80M | 1.86M | 2.28M | 2.37M | 4.28M | 3.46M | 4.54M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 0 | 1.90M | - | 1.00M | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | 200.00K | 100.00K | 0 | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | 7.40M | 900.00K | 0 | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 32.85M | 37.87M | 31.51M | 28.27M |
| Operating Income | - | -12.49M | -21.20M | -28.49M | -43.90M | -34.22M | -15.99M | -23.04M | - | -20.04M | -16.98M | - | -31.95M | -37.87M | -31.51M | -28.27M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | -31.95M | -37.87M | -31.51M | -28.27M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -41.30M | -37.34M | -30.88M | -26.86M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | -237.00K | 0 | - | - | - |
| Net Income | -11.99M | -11.48M | -34.97M | -76.68M | -36.61M | -63.90M | -17.68M | -23.75M | -27.67M | -19.29M | -16.76M | - | -41.30M | -37.34M | -30.88M | -26.86M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -2.11 | - | -2.13 | -1.34 | -0.50 | -0.25 |
| R&D Expense | 7.87M | 3.85M | 14.61M | - | - | - | 11.39M | 6.07M | 8.77M | 7.29M | 9.28M | 15.67M | - | - | - | - |
Compounded Sales Growth
| 5 Years: | -33.33% |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | 11.65% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +444.44% |
| 6 Months: | +546.53% |
| 3 Months: | +88.84% |
| 1 Month: | +99.36% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 7.48M | 30.97M | 54.99M | 87.98M | 80.49M | 82.14M | 6.42M | 33.53M | 16.91M | 16.61M | 46.05M | - | 20.94M | 6.22M | 19.43M | 78.34M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.76M | 3.17M | 16.33M | 75.21M |
| Cash & Equivalents | 5.68M | 6.89M | 47.79M | 32.81M | 47.79M | 23.65M | 1.40M | 5.96M | 2.32M | 5.34M | 7.28M | 35.30M | - | 17.12M | 2.53M | 13.89M | 71.79M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | - |
| Total Liabilities | - | 5.05M | 20.86M | 27.23M | 82.09M | 43.43M | 68.63M | 11.42M | 31.46M | 11.67M | 10.52M | 18.09M | - | 16.09M | 14.20M | 9.97M | 7.47M |
| Current Liabilities | - | 5.03M | 11.20M | 15.92M | 62.47M | 27.23M | 57.07M | 5.76M | 24.57M | 5.97M | 5.29M | 12.34M | - | 15.52M | 13.73M | 9.51M | 7.02M |
| Long Term Debt | - | - | - | 0 | 7.74M | 4.49M | 0 | - | 2.61M | 0 | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 945.00K | 906.00K | 1.00M | 1.00M |
| Total Equity | - | 2.43M | 10.11M | 27.76M | 5.89M | 37.06M | -12.26M | -5.00M | 2.07M | 5.25M | 6.09M | 27.96M | - | 4.85M | -7.98M | 9.46M | 70.87M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | 21.01M | 32.13M | 73.98M | 153.10M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.26M | -14.67M | -20.97M | -28.93M | -42.87M | -48.16M | -11.85M | -10.99M | -30.42M | -17.64M | -10.42M | - | -23.81M | -31.41M | -35.40M | -28.39M |
| Investing Cash Flow | -106.00K | 14.00K | -87.00K | -12.04M | -5.53M | 10.39M | -85.00K | 12.16M | 0 | - | - | 0 | -4.50M | -5.50M | 0 | - |
| Financing Cash Flow | 11.57M | 19.20M | 42.43M | 55.95M | 24.26M | 43.84M | 16.50M | 5.53M | 23.12M | 19.57M | 38.44M | - | 24.08M | 22.32M | 46.76M | 86.30M |
| Capital Expenditure | -106.00K | -53.00K | - | -320.00K | -57.00K | -153.00K | -6.00K | - | - | - | - | - | -4.50M | -5.50M | - | - |
| Free Cash Flow | -10.36M | -14.72M | - | -29.25M | -42.93M | -48.31M | -11.86M | - | - | - | - | - | -28.31M | -36.91M | -35.40M | -28.39M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | -4.23M | -14.60M | 11.36M | 57.91M |
| Share Buybacks | 3.85M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - | - | - | 0 | 487.00K | 0 | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | 90.0% | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | -893.8% | - | -3,195.0% | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | -881.9% | - | -4,130.1% | - | - | - |
| ROE % | -493.5% | -113.6% | -126.0% | -1,302.7% | -98.8% | 521.1% | 353.8% | -1,147.5% | -527.6% | -316.6% | -59.9% | - | -851.4% | 468.2% | -326.3% | -37.9% |
| ROCE % | - | -63.2% | -54.3% | -111.7% | -82.4% | -136.5% | -2,415.1% | -257.2% | - | -177.1% | -50.4% | - | -588.6% | 503.8% | -317.6% | -39.6% |
Shareholding Pattern
Insiders
0.43%
Institutions
29.22%
Public Float
29.34%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 6.56% | 12.20M | $113.57M |
| 2 | State Street Corporation | 4.51% | 8.40M | $78.17M |
| 3 | Vanguard Capital Management LLC | 4.05% | 7.53M | $70.07M |
| 4 | Geode Capital Management, LLC | 2.10% | 3.91M | $36.43M |
| 5 | Marshall Wace LLP | 1.10% | 2.04M | $18.97M |
| 6 | Jones Financial Companies, L.L.L.P. | 0.90% | 1.68M | $15.59M |
| 7 | Vanguard Portfolio Management LLC | 0.79% | 1.46M | $13.62M |
| 8 | Morgan Stanley | 0.72% | 1.34M | $12.44M |
| 9 | Northern Trust Corporation | 0.69% | 1.28M | $11.88M |
| 10 | Vanguard Fiduciary Trust Co | 0.65% | 1.20M | $11.20M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SLS
No recent headlines available.